Invitrogen

Phospho-EGFR (Tyr1086) Polyclonal Antibody

Advanced Verification

This Antibody was verified by Cell treatment to ensure that the antibody binds to the antigen stated.

7 Published Figures

17 References

View all (279) EGFR antibodies

Datasheet

Protocols

Questions & Answers

Datasheet

Protocols

Questions & Answers

Phospho-EGFR (Tyr1086) Antibody in Immunocytochemistry (ICC/IF)

FIGURE: 1 / 15

Phospho-EGFR (Tyr1086) Antibody (36-9700) in ICC/IF

Immunofluorescent staining of EGF-stimulated A431 cells using our Rabbit anti-phospho-EGFr (Tyr1086) polyclonal antibody (Product # 36-9700).

Phospho-EGFR (Tyr1086) Antibody in Western Blot (WB)

Phospho-EGFR (Tyr1086) Antibody in Immunoprecipitation (IP)

Phospho-EGFR (Tyr1086) Antibody in Western Blot, Immunohistochemistry, Immunohistochemistry (Paraffin) (WB, IHC, IHC (P))

Phospho-EGFR (Tyr1086) Antibody in Immunohistochemistry (IHC)

Product Image Gallery

Product Details

36-9700

Applications

Tested Dilution

Publications

Western Blot (WB)

0.5 µg/mL

View 7 publications 7 publications

Immunohistochemistry (IHC)

Assay-dependent

View 8 publications 8 publications

Immunohistochemistry (Paraffin) (IHC (P))

View 1 publication 1 publication

Immunocytochemistry (ICC/IF)

Assay-dependent

View 1 publication 1 publication

ELISA (ELISA)

Assay-dependent

Immunoprecipitation (IP)

0.1-0.5 µg/mL

Product Specifications

Species Reactivity

Human, Mouse, Rat

Published species

Human, Mouse, Rat

Host/Isotype

Rabbit / IgG

Class

Polyclonal

Type

Antibody

Immunogen

Synthetic peptide derived from the region surrounding the phosphorylated Tyr1086 residue of the human, mouse, rat, and pig epidermal growth factor receptor (EGFr) protein.

View immunogen

Conjugate

Unconjugated Unconjugated Unconjugated

Form

Liquid

Concentration

0.25 mg/mL

Purification

Antigen affinity chromatography

Storage buffer

PBS, pH 7.4

Contains

0.1% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2533287

Target Information

EGFR, epidermal growth factor receptor, is a receptor tyrosine kinases that signals in response to various growth factors. Overexpression has been linked to numerous types of cancer and EGFR is the target of both biological and small molecular therapeutics. EGFR is encoded by the EGFR gene located on chromosome 7 in humans. EGFR belongs to the HER/ERbB family of proteins that includes three other receptor tyrosine kinases, ERbB2, ERbB3, ERbB4. EGFR is a transmembrane receptor and binding of its cognate ligands such as EGF (Epidermal Growth Factor) and TGF alpha (Transforming Growth Factor alpha) to the extracellular domain leads to EGFR dimerization followed by autophosphorylation of the tyrosine residues in the cytoplasmic domain. Overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.

Product References

Spatial Metabolomics Identifies Distinct Tumor-Specific Subtypes in Gastric Cancer Patients.

Clinical cancer research : an official journal of the American Association for Cancer Research

Wang J,Kunzke T,Prade VM,Shen J,Buck A,Feuchtinger A,Haffner I,Luber B,Liu DHW,Langer R,Lordick F,Sun N,Walch A

36-9700 was used in Immunohistochemistry to define metabolically distinct gastric cancer subtypes and identify their clinicopathological and molecular characteristics.

Fri Jul 01 00:00:00 EDT 2022

Afatinib restrains K-RAS-driven lung tumorigenesis.

Science translational medicine

Moll HP,Pranz K,Musteanu M,Grabner B,Hruschka N,Mohrherr J,Aigner P,Stiedl P,Brcic L,Laszlo V,Schramek D,Moriggl R,Eferl R,Moldvay J,Dezso K,Lopez-Casas PP,Stoiber D,Hidalgo M,Penninger J,Sibilia M,Győrffy B,Barbacid M,Dome B,Popper H,Casanova E

36-9700 was used in Immunohistochemistry to provide evidence that epidermal growth factor receptor signaling is engaged in K-RAS-driven lung tumorigenesis in humans and in mice.

Wed Jun 20 00:00:00 EDT 2018

Effects of general anesthesia with or without epidural block on tumor metastasis and mechanisms.

Oncology letters

Yang B,Qian F,Li W,Li Y,Han Y

36-9700 was used in Western Blotting to assess whether different anaesthesia methods were associated with tumour metastasis during the perioperative period and the possible molecular mechanisms of tumour metastasis.

Sun Apr 01 00:00:00 EDT 2018

Overcoming EGFR^G724S-mediated osimertinib resistance through unique binding characteristics of second-generation EGFR inhibitors.

Nature communications

Fassunke J,Müller F,Keul M,Michels S,Dammert MA,Schmitt A,Plenker D,Lategahn J,Heydt C,Brägelmann J,Tumbrink HL,Alber Y,Klein S,Heimsoeth A,Dahmen I,Fischer RN,Scheffler M,Ihle MA,Priesner V,Scheel AH,Wagener S,Kron A,Frank K,Garbert K,Persigehl T,Püsken M,Haneder S,Schaaf B,Rodermann E,Engel-Riedel W,Felip E,Smit EF,Merkelbach-Bruse S,Reinhardt HC,Kast SM,Wolf J,Rauh D,Büttner R,Sos ML

Published figure using Phospho-EGFR (Tyr1086) polyclonal antibody (Product # 36-9700) in Western Blot

Wed Nov 07 00:00:00 EST 2018

Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma.

Nature medicine

Mai WX,Gosa L,Daniels VW,Ta L,Tsang JE,Higgins B,Gilmore WB,Bayley NA,Harati MD,Lee JT,Yong WH,Kornblum HI,Bensinger SJ,Mischel PS,Rao PN,Clark PM,Cloughesy TF,Letai A,Nathanson DA

36-9700 was used in Western Blotting to identify a crucial link among oncogene signaling, glucose metabolism, and cytoplasmic p53.

Wed Nov 01 00:00:00 EDT 2017

Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.

Oncology letters

Zhang Y,Yang J,Ding M,Li L,Lu Z,Zhang Q,Zheng J

369700 was used in immunohistochemistry - paraffin section and western blot to improve the therapeutic efficacy of cetuximab for non-small cell lung cancer by co-administrating the tumor-penetrating internalizing RGD peptide

Tue Nov 01 00:00:00 EDT 2016

Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.

Oncology letters

Zhang Y,Yang J,Ding M,Li L,Lu Z,Zhang Q,Zheng J

Tue Nov 01 00:00:00 EDT 2016

Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.

Oncology letters

Zhang Y,Yang J,Ding M,Li L,Lu Z,Zhang Q,Zheng J

Tue Nov 01 00:00:00 EDT 2016

Preclinical evaluation of afatinib (BIBW2992) in esophageal squamous cell carcinoma (ESCC).

American journal of cancer research

Wong CH,Ma BB,Hui CW,Tao Q,Chan AT

36-9700 was used in Western Blotting to characterise the preclinical activity of afatinib in five oesophageal squamous cell carcinoma cell lines: HKESC-1, HKESC-2, KYSE510, SLMT-1 and EC-1.

Wed Feb 17 00:00:00 EST 2016

Resistance to EGF receptor inhibitors in glioblastoma mediated by phosphorylation of the PTEN tumor suppressor at tyrosine 240.

Proceedings of the National Academy of Sciences of the United States of America

Fenton TR,Nathanson D,Ponte de Albuquerque C,Kuga D,Iwanami A,Dang J,Yang H,Tanaka K,Oba-Shinjo SM,Uno M,Inda MM,Wykosky J,Bachoo RM,James CD,DePinho RA,Vandenberg SR,Zhou H,Marie SK,Mischel PS,Cavenee WK,Furnari FB

Tue Aug 28 00:00:00 EDT 2012

Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).

BMC cancer

Luber B,Deplazes J,Keller G,Walch A,Rauser S,Eichmann M,Langer R,Höfler H,Hegewisch-Becker S,Folprecht G,Wöll E,Decker T,Endlicher E,Lorenzen S,Fend F,Peschel C,Lordick F

Wed Dec 07 00:00:00 EST 2011

Epithelial-to-mesenchymal transition in the development and progression of adenocarcinoma and squamous cell carcinoma of the lung.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Prudkin L,Liu DD,Ozburn NC,Sun M,Behrens C,Tang X,Brown KC,Bekele BN,Moran C,Wistuba II

Fri May 01 00:00:00 EDT 2009

Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.

Cancer research

Bremm A,Walch A,Fuchs M,Mages J,Duyster J,Keller G,Hermannstädter C,Becker KF,Rauser S,Langer R,von Weyhern CH,Höfler H,Luber B

Fri Feb 01 00:00:00 EST 2008

Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.

Cancer research

Bremm A,Walch A,Fuchs M,Mages J,Duyster J,Keller G,Hermannstädter C,Becker KF,Rauser S,Langer R,von Weyhern CH,Höfler H,Luber B

Fri Feb 01 00:00:00 EST 2008

Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.

Cancer research

Bremm A,Walch A,Fuchs M,Mages J,Duyster J,Keller G,Hermannstädter C,Becker KF,Rauser S,Langer R,von Weyhern CH,Höfler H,Luber B

Fri Feb 01 00:00:00 EST 2008

Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations.

Cancer research

Bremm A,Walch A,Fuchs M,Mages J,Duyster J,Keller G,Hermannstädter C,Becker KF,Rauser S,Langer R,von Weyhern CH,Höfler H,Luber B

Fri Feb 01 00:00:00 EST 2008

Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.

Toxicology and applied pharmacology

Barrick CJ,Yu M,Chao HH,Threadgill DW

Thu May 01 00:00:00 EDT 2008

Chronic pharmacologic inhibition of EGFR leads to cardiac dysfunction in C57BL/6J mice.

Toxicology and applied pharmacology

Barrick CJ,Yu M,Chao HH,Threadgill DW

Thu May 01 00:00:00 EDT 2008

Clinicopathologic characteristics of the EGFR gene mutation in non-small cell lung cancer.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Tsao AS,Tang XM,Sabloff B,Xiao L,Shigematsu H,Roth J,Spitz M,Hong WK,Gazdar A,Wistuba I

Wed Mar 01 00:00:00 EST 2006

Bioinformatics

Protein Aliases: 2.7.10.1; avian erythroblastic leukemia viral (v-erb-b) oncogene homolog; avian erythroblastic leukemia viral (v-erbB) oncogene homolog; cell growth inhibiting protein 40; cell proliferation-inducing protein 61; EC 2.7.10.1; EGFR-related peptide; Epidermal growth factor receptor; Epidermal growth factor receptor formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); epidermal growth factor receptor, formerly avian erythroblastic leukemia viral (v-erbB) oncogene homolog (Erbb1); erb-b2 receptor tyrosine kinase 1; kinase EGFR; Oncogene ERBB; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; Urogastrone; waved 2

View more View less

Gene Aliases: 9030024J15Rik; AI552599; EGFR; ERBB; ErbB-1; ERBB1; Errb1; Errp; HER1; mENA; NISBD2; PIG61; wa-2; wa2; Wa5

View more View less

UniProt ID: (Human) P00533, (Mouse) Q01279

View more View less

Entrez Gene ID: (Human) 1956, (Mouse) 13649, (Rat) 24329

View more View less

Function(s)

chromatin binding double-stranded DNA binding MAP kinase kinase kinase activity protein tyrosine kinase activity transmembrane receptor protein tyrosine kinase activity receptor signaling protein tyrosine kinase activity transmembrane signaling receptor activity epidermal growth factor-activated receptor activity Ras guanyl-nucleotide exchange factor activity protein binding ATP binding enzyme binding protein phosphatase binding nitric-oxide synthase regulator activity ubiquitin protein ligase binding identical protein binding phosphatidylinositol-4,5-bisphosphate 3-kinase activity protein heterodimerization activity actin filament binding cadherin binding involved in cell-cell adhesion nucleotide binding glycoprotein binding protein kinase activity signal transducer activity receptor binding integrin binding kinase activity transferase activity transferase activity, transferring phosphorus-containing groups protein kinase binding epidermal growth factor binding transmembrane signal receptor

Process(es)

Performance Guarantee

If an Invitrogen™ antibody doesn't perform as described on our website or datasheet,we'll replace the product at no cost to you, or provide you with a credit for a future purchase.*

Learn more

Phospho-EGFR (Tyr1086) Polyclonal Antibody

Phospho-EGFR (Tyr1086) Antibody (36-9700) in ICC/IF

Product Details

36-9700

Western Blot (WB)

Immunohistochemistry (IHC)

Immunohistochemistry (Paraffin) (IHC (P))

Immunocytochemistry (ICC/IF)

ELISA (ELISA)

Immunoprecipitation (IP)

Species Reactivity

Published species

Host/Isotype

Class

Type

Immunogen

Conjugate

Form

Concentration

Purification

Storage buffer

Contains

Storage conditions

Shipping conditions

RRID

Target Information

Bioinformatics

Performance Guarantee

We're here to help

Your items have has been added!